NCT02005133View on ClinicalTrials.gov

A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

TerminatedOBSERVATIONAL
Enrollment

188

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Wet Age-related Macular Degeneration
Trial Locations (17)

TA1 5DA

Novartis Investigative Site, Taunton

GU16 7UJ

Novartis Investigative Site, Frimley

EC1V 2PD

Novartis Investigative Site, London

BD9 6RJ

Novartis Investigative Site, Bradford

LS9 7TF

Novartis Investigative Site, Leeds

BL4 0JR

Novartis Investigative Site, Bolton

BS1 2LX

Novartis Investigative Site, Bristol

GU2 5XX

Novartis Investigative Site, Guildford, Surrey

CT1 3NG

Novartis Investigative Site, Kent

L7 8XP

Novartis Investigative Site, Liverpool

SE5 9RS

Novartis Investigative Site, London

NE1 4LP

Novartis Investigative Site, Newcastle upon Tyne

SO16 6YD

Novartis Investigative Site, Southampton

SS0 0RY

Novartis Investigative Site, Southend

SR2 9HP

Novartis Investigative Site, Sunderland

UB8 3NN

Novartis Investigative Site, Uxbridge

YO31 8HE

Novartis Investigative Site, York

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT02005133 - A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics | Biotech Hunter | Biotech Hunter